´ëÇѵÎÅëÇÐȸ 2024³â Ãá°èÇмú´ëȸ : 2024-06-23
±³À°ÀÏÀÚ : 2024-06-23
±³À°Àå¼Ò : ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ
±³À°ÁÖÁ¦ : ´ëÇѵÎÅëÇÐȸ 2024³â Ãá°èÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇѵÎÅëÇÐȸ
´ã´çÀÚ : ±èÀ¯Áø
¿¬¶ôó : 02-974-8606
À̸ÞÀÏ : kheadache2014@gmail.com
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, ½Å°æ¿Ü°ú, À̺ñÀÎÈÄ°ú, ½Å°æ°ú, °¡Á¤ÀÇÇаú, ÀÀ±ÞÀÇÇаú, ÀÇ»çÇÐ, ÀÇÇб³À°
Âü¼®¿¹»óÀÎ : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 8 ½Ã°£ 46ºÐ
¼¼ºÎ¼ö°·á : 80,000¿ø
ºñ°í <»çÀüµî·Ï>Æò»ýȸ¿ø¹×2024¿¬È¸ºñ³³ºÎÁ¤È¸¿ø40,000¿ø,¹Ì³³Á¤È¸¿ø70,000¿ø,ÁØȸ¿ø Àü°øÀÇ ¹«·á, ÁØȸ¿ø(±âŸȸ¿ø,±ºÀÇ°ü,°øº¸ÀÇ)40,000¿ø,ºñȸ¿ø70,000¿ø <ÇöÀåµî·Ï>Æò»ýȸ¿ø¹×2024¿¬È¸ºñ³³ºÎÁ¤È¸¿ø50,000¿ø,¹Ì³³Á¤È¸¿ø80,000¿ø,ÁØȸ¿ø Àü°øÀÇ ¹«·á, ÁØȸ¿ø(±âŸȸ¿ø,±ºÀÇ°ü,°øº¸ÀÇ)50,000¿ø,ºñȸ¿ø80,000¿ø <¿öÅ©¼¥> 40,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 09:10~09:30 Genetics in Migraine and Cluster (ÆíµÎÅë°ú ±º¹ßµÎÅëÀÇ À¯ÀüÇÐ) ±èÁØÈ£(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 09:30~09:50 Glymphatic System and Migraine (ÆíµÎÅë¿¡¼ ±Û¸²ÆÄƽ½ºÀÇ ¿ªÇÒ) ¹Ú°¹Î(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 09:50~10:10 Pharmacological and Non-Pharmacological Treatment in Pediatric Migraine (¼Ò¾ÆÆíµÎÅë¿¡¼ ¾à¹° ¹× ºñ¾à¹°Ä¡·á) º¯¼ºÈ¯(ºÐ´çÁ¦»ýº´¿ø)
±³À°½Ã°£ 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 10:10~10:30 Neuromodulation in Migriane and Cluster (ÆíµÎÅë °ú ±º¹ßµÎÅë¿¡¼ ½Å°æÁ¶ÀýÄ¡·á) ÀÌÇýÁ¤(Áß¾ÓÀÇ´ë)
Åä·Ð 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 10:30~10:45 Q & A -(-)
ÈÞ½Ä 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 10:45~11:00 Coffee Break -(-)
±³À°½Ã°£ 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 11:00~11:13 (±¸¿¬¹ßÇ¥: A ROOM) Association Between Cortical Thickness and Response to Anti-CGRP Monoclonal Antibodies in Patients with Chronic Migraine Á¶¼öÇö(À»ÁöÀÇ´ë)
±³À°½Ã°£ 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 11:13~11:26 (±¸¿¬¹ßÇ¥: A ROOM) Is Idiopathic Intracranial Hypertension Really Rare in Asia? A Prospective Multicenter Headache Clinic-based Study about the Frequency of Idiopathic Intracranial Hypertension ±èº´¼ö(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 11:26~11:39 (±¸¿¬¹ßÇ¥: A ROOM) Effect of Migraine on Suicide Mortality in Young Adults: A Nationwide Cohort Study in South Korea ±è½Â¾Ö(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 11:39~11:52 (±¸¿¬¹ßÇ¥: A ROOM) Decreased Interictal Serum Butyrate but Unchanged Acetate and Propionate Levels in Individuals with Episodic and Chronic Migraine Á¶¼ö¹Ì(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 11:52~12:05 (±¸¿¬¹ßÇ¥: A ROOM) Clinical Profile and Disease Course of Visual Snow: The First Prospective Asian Cohort with Validation of Diagnostic Criteria À̽ÂÇö(ÀüºÏÀÇ´ë)
±³À°½Ã°£ 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 12:05~12:18 (±¸¿¬¹ßÇ¥: A ROOM) Efficacy of CGRP Monoclonal Antibodies on Persistent Headaches Following COVID-19 Infection ¼ÛÅÂÁø(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ½Å¶óȦ 1+2+3 11:00~11:13 (±¸¿¬¹ßÇ¥: B ROOM) Eight-teen Years of Triptan Use in Korea: A Nationwide Population-Based Study ÇÏ¿ì¼®(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ½Å¶óȦ 1+2+3 11:13~11:26 (±¸¿¬¹ßÇ¥: B ROOM) Is Tension-type Headache Bilateral? Population Based Subgroup Analysis of Tension-type Headache ÀÌ¿ø¿ì(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ½Å¶óȦ 1+2+3 11:26~11:39 (±¸¿¬¹ßÇ¥: B ROOM) Structural Connectome Alterations in Patients with Episodic Migraine ³ëÀºÂù(ÀÎÇÏÀÇ´ë)
±³À°½Ã°£ 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ½Å¶óȦ 1+2+3 11:39~11:52 (±¸¿¬¹ßÇ¥: B ROOM) Exercise As an Abortive Treatment for Cluster Headaches: A Single-center Survey in Korea and A Case Report °¹Ì°æ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ½Å¶óȦ 1+2+3 11:52~12:05 (±¸¿¬¹ßÇ¥: B ROOM) Rapid Eye Movement Sleep-Dependent Obstructive Sleep Apnea among Patients with mild Obstructive Sleep Apnea and Migraine or Cluster Headache È«À¯È(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ½Å¶óȦ 1+2+3 12:05~12:18 (±¸¿¬¹ßÇ¥: B ROOM) Real-world Experience of Lasmiditan for The Acute Treatment of Migraine: A Single Clinic-based Prospective Study Á¤È¸Á¾(¼¿ïÀÇ´ë)
ÈÞ½Ä 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 12:18~13:10 General Assembly, Award, and Lunch -(-)
±³À°½Ã°£ 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 13:10~13:30 Migraine Precursors and Migraine in Children (¾Æµ¿±â ÆíµÎÅë ¼±ÇàÁõ°ú ÆíµÎÅë) ÀÌÀ±Áø(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 13:30~13:50 Migraine in Adolescents (û¼Ò³â ½Ã±âÀÇ ÆíµÎÅë) ±ÇÇýÀº(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 13:50~14:10 Migraine in Menopause and Perimenopause (Æó°æ±â¿Í Æó°æÀüÈıâÀÇ ÆíµÎÅë) ±è¼ö°æ(°æ»óÀÇ´ë)
±³À°½Ã°£ 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 14:10~14:30 Migraine in Older Adults (³ë³â±âÀÇ ÆíµÎÅë) ¼ÛÅÂÁø(ÀÌÈÀÇ´ë)
Åä·Ð 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 14:30~14:45 Q & A -(-)
ÈÞ½Ä 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 14:45~15:00 Coffee Break -(-)
±³À°½Ã°£ 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 15:00~15:30 RCTs and Real World Evidence of Gepants (°ÔÆÇÆ® Ä¡·á) Á¶¼öÇö(À»ÁöÀÇ´ë)
±³À°½Ã°£ 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 15:30~16:00 Good Responders and Non-Responders (CGRPÇ¥ÀûÄ¡·áÀÇ ¹ÝÀÀ ¿¹Ãø) ¹®Èñ¼ö(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 16:00~16:30 Treatment-Related Adverse Events and Management (CGRPÇ¥ÀûÄ¡·áÀÇ ºÎÀÛ¿ë°ú °ü¸®) ¹ÚÁ¤¿í(°¡Å縯ÀÇ´ë)
Åä·Ð 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 16:30~16:40 Q & A -(-)
±³À°½Ã°£ 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 16:50~17:30 Nerve Blocks in Headache Disorders (µÎÅëÁúȯ¿¡¼ ½Å°æÂ÷´Ü¼ú) ¹è´ë¿õ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 06¿ù 23ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 17:30~18:10 Botulinum Toxin Injection in Chronic Migraine (¸¸¼ºÆíµÎÅë¿¡¼ º¸Åø¸®´®µ¶¼Ò Ä¡·á) ÀÌ¿ø¿ì(¿¬¼¼ÀÇ´ë)